Amgen Lumakras combination data in lung cancer held until August - Reuters
Mohammed Haneefa Nizamudeen


Data on Amgen's Lumakras (sotorasib) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) and Roche's (OTCQX:RHHBY) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported.
Results will be released at the 2022 World Conference on Lung Cancer.

Conference organizers released data Tuesday from a small trial of Lumakras combined with RMC-4630 from Revolution Medicine (RVMD) and Sanofi (SNY). The trial enrolled 11 patients with severe non-small cell lung cancer (NSCLC). Results showed three patients had tumor shrinkage and seven had stable disease.
Lumakras was approved in 2021 under the U.S. FDA's Accelerated Approval program as a second-line NSCLC treatment. Amgen (NASDAQ:AMGN) is eying further indications of the drug in earlier stages of lung cancer.
The drug may eventually compete with Mirati Therapeutics' (NASDAQ:MRTX) experimental adagrasib, which like Lumakras, is a KRAS inhibitor. Adagrasib is also under investigation for colorectal cancer.
Lumakras annual revenues could reach $1.5B by 2026-2027, according to Seeking Alpha contributor Natalie Koo.